Clinical Trial Update: Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of sorafenib in never-smokers with lung adenocarcinoma (formerly bronchioloalveolar carcinoma) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Swedish Medical Center | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED